首页 > 最新文献

JAMA Health Forum最新文献

英文 中文
Change of Ownership and Quality of Home Health Agency Care. 所有权变更与居家医疗机构的护理质量。
IF 9.5 Q1 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-11-01 DOI: 10.1001/jamahealthforum.2024.3767
Zhanji Zhang, Kun Li, Siyi Wang, Shekinah Fashaw-Walters, Yucheng Hou

Importance: The home health agency (HHA) market has seen increasingly more change in ownership transactions. Little is known about the organizational characteristics and quality of care of HHAs after ownership has changed.

Objective: To examine whether an HHA change in ownership was associated with different quality-of-care outcomes, patient volume, and staffing levels.

Design, setting, and participants: Using current HHA change of ownership files linked to publicly available Medicare HHA data, this staggered difference-in-differences analysis evaluated ownership change transactions of Medicare-certified HHAs from quarter 1 of 2016 to quarter 4 of 2019. Pretransaction and posttransaction HHA characteristics and quality-of-care outcomes were compared between HHAs that changed ownership and up to 8 matched controls. The transactions in the main analysis included (1) when an HHA remained as for-profit with a change in ownership and (2) when an HHA changed from nonprofit/public to for-profit ownership. The data were analyzed between November 2023 and September 2024.

Main outcomes and measures: The primary outcomes were HHA-quarter measures of star ratings, the individual quality measures that compose the star ratings based on the Outcome and Assessment Information Set, and claims-based quality metrics, such as hospitalizations and emergency department visits. The secondary outcomes included HHA year measures of Medicare patient volume, per capita payments, and staffing levels (full-time equivalents and minutes per visit).

Results: The main dataset included 294 Medicare-certified HHAs that changed ownership, matched with 2330 controls. In 3 years after an ownership change, quarterly star ratings increased by 0.18 (95% CI, 0.05-0.31) relative to matched controls, with greater increases among HHAs that converted from nonprofit/public to for-profit. No significant improvement was observed in the 60-day rates of hospital admissions or outpatient emergency department visits. Further, no significant changes were observed in the number of Medicare beneficiaries, but per capita payments increased within 2 years post-ownership change. Significant reductions were observed in full-time equivalents of registered nurses (-17% [95% CI, -31% to -3%]) and home health aides (-26% [95% CI, -39% to -13%]), as well as per-visit minutes for skilled nursing care (-5% [95% CI, -9% to -1%]), physical therapy (-3% [95% CI, -5% to 0%]), and home health aide care (-11% [95% CI, -15% to -6%]).

Conclusions and relevance: In this difference-in-differences analysis of Medicare-certified HHAs, ownership change was associated with higher star ratings and Medicare per capita payments, but not with claims-based quality measures. Reduction in staffing levels after ownership change raises concerns about implications for quality of care.

重要性:家庭保健机构(HHA)市场的所有权交易变化越来越多。人们对所有权变更后家庭医疗机构的组织特征和护理质量知之甚少:目的:研究家庭医疗机构所有权变更是否与不同的护理质量结果、患者数量和人员配置水平有关:这项交错差异分析利用当前的 HHA 所有权变更文件与公开的 Medicare HHA 数据相链接,评估了 2016 年第 1 季度至 2019 年第 4 季度期间 Medicare 认证的 HHA 所有权变更交易。在所有权发生变化的 HHA 和多达 8 个匹配对照之间比较了交易前和交易后 HHA 的特征和护理质量结果。主要分析中的交易包括:(1)所有权发生变化但仍为营利性的 HHA;(2)HHA 的所有权从非营利性/公共性转变为营利性。数据分析时间为 2023 年 11 月至 2024 年 9 月:主要结果包括 HHA 季度星级评定、基于结果和评估信息集的星级评定的单项质量指标,以及基于索赔的质量指标,如住院和急诊就诊。次要结果包括医疗保险(Medicare)患者数量、人均支付和人员配备水平(全职当量和每次就诊分钟数)的 HHA 年度衡量指标:主要数据集包括 294 家经联邦医疗保险认证、所有权发生变更的 HHA,以及 2330 家对照机构。在所有权变更后的 3 年内,季度星级评分相对于匹配的对照组提高了 0.18(95% CI,0.05-0.31),其中从非营利/公立转为营利的医疗保健机构的星级评分提高幅度更大。在 60 天入院率或门诊急诊就诊率方面没有观察到明显改善。此外,在医疗保险受益人数量方面也没有观察到明显变化,但在所有权改变后的两年内,人均支付额有所增加。在相当于全职的注册护士(-17% [95% CI, -31% to -3%])和家庭健康助理(-26% [95% CI, -39% to -13%])以及专业护理(-5% [95% CI, -9% to -1%] )、物理治疗(-3% [95% CI, -5% to 0%])和家庭健康助理护理(-11% [95% CI, -15% to -6%])的每次就诊分钟数方面,观察到了显著的减少:在这项对获得医疗保险认证的保健护理机构进行的差异分析中,所有权变更与较高的星级评定和医疗保险人均支付有关,但与基于索赔的质量衡量标准无关。所有权变更后人员配备水平的降低引发了对护理质量影响的担忧。
{"title":"Change of Ownership and Quality of Home Health Agency Care.","authors":"Zhanji Zhang, Kun Li, Siyi Wang, Shekinah Fashaw-Walters, Yucheng Hou","doi":"10.1001/jamahealthforum.2024.3767","DOIUrl":"10.1001/jamahealthforum.2024.3767","url":null,"abstract":"<p><strong>Importance: </strong>The home health agency (HHA) market has seen increasingly more change in ownership transactions. Little is known about the organizational characteristics and quality of care of HHAs after ownership has changed.</p><p><strong>Objective: </strong>To examine whether an HHA change in ownership was associated with different quality-of-care outcomes, patient volume, and staffing levels.</p><p><strong>Design, setting, and participants: </strong>Using current HHA change of ownership files linked to publicly available Medicare HHA data, this staggered difference-in-differences analysis evaluated ownership change transactions of Medicare-certified HHAs from quarter 1 of 2016 to quarter 4 of 2019. Pretransaction and posttransaction HHA characteristics and quality-of-care outcomes were compared between HHAs that changed ownership and up to 8 matched controls. The transactions in the main analysis included (1) when an HHA remained as for-profit with a change in ownership and (2) when an HHA changed from nonprofit/public to for-profit ownership. The data were analyzed between November 2023 and September 2024.</p><p><strong>Main outcomes and measures: </strong>The primary outcomes were HHA-quarter measures of star ratings, the individual quality measures that compose the star ratings based on the Outcome and Assessment Information Set, and claims-based quality metrics, such as hospitalizations and emergency department visits. The secondary outcomes included HHA year measures of Medicare patient volume, per capita payments, and staffing levels (full-time equivalents and minutes per visit).</p><p><strong>Results: </strong>The main dataset included 294 Medicare-certified HHAs that changed ownership, matched with 2330 controls. In 3 years after an ownership change, quarterly star ratings increased by 0.18 (95% CI, 0.05-0.31) relative to matched controls, with greater increases among HHAs that converted from nonprofit/public to for-profit. No significant improvement was observed in the 60-day rates of hospital admissions or outpatient emergency department visits. Further, no significant changes were observed in the number of Medicare beneficiaries, but per capita payments increased within 2 years post-ownership change. Significant reductions were observed in full-time equivalents of registered nurses (-17% [95% CI, -31% to -3%]) and home health aides (-26% [95% CI, -39% to -13%]), as well as per-visit minutes for skilled nursing care (-5% [95% CI, -9% to -1%]), physical therapy (-3% [95% CI, -5% to 0%]), and home health aide care (-11% [95% CI, -15% to -6%]).</p><p><strong>Conclusions and relevance: </strong>In this difference-in-differences analysis of Medicare-certified HHAs, ownership change was associated with higher star ratings and Medicare per capita payments, but not with claims-based quality measures. Reduction in staffing levels after ownership change raises concerns about implications for quality of care.</p>","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":null,"pages":null},"PeriodicalIF":9.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11530943/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142559433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Curious Persistence of Site-Dependent Payments. 取决于地点的付款的奇特持续性。
IF 9.5 Q1 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-11-01 DOI: 10.1001/jamahealthforum.2024.3616
Barak D Richman, Elizabeth Plummer, Ge Bai
{"title":"The Curious Persistence of Site-Dependent Payments.","authors":"Barak D Richman, Elizabeth Plummer, Ge Bai","doi":"10.1001/jamahealthforum.2024.3616","DOIUrl":"https://doi.org/10.1001/jamahealthforum.2024.3616","url":null,"abstract":"","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":null,"pages":null},"PeriodicalIF":9.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142559437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Using Bayh-Dole Act March-In Rights to Lower US Drug Prices. 利用《贝-多尔法案》的进军权降低美国药品价格。
IF 9.5 Q1 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-11-01 DOI: 10.1001/jamahealthforum.2024.3775
Lisa Larrimore Ouellette, Bhaven N Sampat

Importance: In December 2023, the Biden-Harris Administration released a proposed framework for exercising government march-in rights (effectively granting compulsory licenses for those patents to generic drug makers) under the Bayh-Dole Act on patents on taxpayer-funded drugs, which has renewed questions about whether march-in rights could promote cost savings through generic competition or harm pharmaceutical innovation.

Objectives: To determine the feasibility of using march-in rights to remove patent barriers to generic competition.

Design, setting, and participants: This cross-sectional study examined government funding information from multiple sources for patents listed in the Food and Drug Administration (FDA) Orange Book from 1985 to 2023. Data analysis was completed in August 2024.

Exposures: New drug applications (NDAs) with Orange Book-listed patents, including (1) all new molecular entities (NMEs) approved from 1985 to 2022; (2) all NDAs with an Orange Book patent listed between 1985 and 2023; and (3) NDAs with unexpired patents listed in a recent (October 2023) edition of the Orange Book.

Main outcomes and measures: The main outcome was whether the drugs had any or all patents that were public-sector patents subject to the Bayh-Dole Act, based on combining different data sources for identifying patents that resulted from federal funding. Public-sector patents resulting from intramural research, which are not subject to march-in rights under the Bayh-Dole Act, were identified separately.

Results: Of 883 new molecular entities approved from 1985 to 2022, 68 (8%) had a Bayh-Dole patent, but only 18 (2%) had solely Bayh-Dole patents. Of 2832 drugs with patents listed for 1985 to 2023, 142 (5%) had a Bayh-Dole patent, but only 38 (1%) had solely Bayh-Dole patents. Of 1213 drugs with Orange Book patents listed in October 2023, 41 (3%) had a Bayh-Dole patent, but only 14 (1%) had solely Bayh-Dole patents.

Conclusion and relevance: This cross-sectional study found that, although Bayh-Dole march-in rights could remove patent barriers to generic entry for a few drugs, their overall effect would be limited.

重要性:2023 年 12 月,拜登-哈里斯政府(Biden-Harris Administration)根据《贝-多尔法案》(Bayh-Dole Act)就纳税人资助药品的专利权发布了一项行使政府进军权(实际上是向仿制药制造商授予这些专利的强制许可)的拟议框架,这再次引发了关于进军权是否能通过仿制药竞争促进成本节约或损害制药创新的问题:目的:确定使用 "进入权 "消除专利对仿制药竞争的障碍的可行性:这项横断面研究从多个来源考察了1985年至2023年食品药品管理局(FDA)桔皮书中所列专利的政府资助信息。数据分析于 2024 年 8 月完成:具有桔皮书所列专利的新药申请(NDA),包括(1)1985年至2022年期间批准的所有新分子实体(NME);(2)1985年至2023年期间具有桔皮书所列专利的所有NDA;以及(3)具有最近(2023年10月)版桔皮书所列未到期专利的NDA:主要结果是药物是否拥有任何或所有受 Bayh-Dole 法案约束的公共部门专利,其依据是综合不同的数据来源,以确定由联邦资助产生的专利。由校内研究产生的公共部门专利不受《贝-多尔法》规定的 "进军权 "的限制,这些专利将被单独识别:在 1985 年至 2022 年期间批准的 883 个新分子实体中,有 68 个(8%)拥有 Bayh-Dole 专利,但只有 18 个(2%)仅拥有 Bayh-Dole 专利。在 1985 年至 2023 年期间获得专利的 2832 种药物中,142 种(5%)拥有 Bayh-Dole 专利,但只有 38 种(1%)仅拥有 Bayh-Dole 专利。在 2023 年 10 月拥有桔皮书专利的 1213 种药物中,41 种(3%)拥有 Bayh-Dole 专利,但只有 14 种(1%)仅拥有 Bayh-Dole 专利:这项横向研究发现,尽管 Bayh-Dole 进军权可以消除少数药品进入仿制药市场的专利障碍,但其总体效果有限。
{"title":"Using Bayh-Dole Act March-In Rights to Lower US Drug Prices.","authors":"Lisa Larrimore Ouellette, Bhaven N Sampat","doi":"10.1001/jamahealthforum.2024.3775","DOIUrl":"10.1001/jamahealthforum.2024.3775","url":null,"abstract":"<p><strong>Importance: </strong>In December 2023, the Biden-Harris Administration released a proposed framework for exercising government march-in rights (effectively granting compulsory licenses for those patents to generic drug makers) under the Bayh-Dole Act on patents on taxpayer-funded drugs, which has renewed questions about whether march-in rights could promote cost savings through generic competition or harm pharmaceutical innovation.</p><p><strong>Objectives: </strong>To determine the feasibility of using march-in rights to remove patent barriers to generic competition.</p><p><strong>Design, setting, and participants: </strong>This cross-sectional study examined government funding information from multiple sources for patents listed in the Food and Drug Administration (FDA) Orange Book from 1985 to 2023. Data analysis was completed in August 2024.</p><p><strong>Exposures: </strong>New drug applications (NDAs) with Orange Book-listed patents, including (1) all new molecular entities (NMEs) approved from 1985 to 2022; (2) all NDAs with an Orange Book patent listed between 1985 and 2023; and (3) NDAs with unexpired patents listed in a recent (October 2023) edition of the Orange Book.</p><p><strong>Main outcomes and measures: </strong>The main outcome was whether the drugs had any or all patents that were public-sector patents subject to the Bayh-Dole Act, based on combining different data sources for identifying patents that resulted from federal funding. Public-sector patents resulting from intramural research, which are not subject to march-in rights under the Bayh-Dole Act, were identified separately.</p><p><strong>Results: </strong>Of 883 new molecular entities approved from 1985 to 2022, 68 (8%) had a Bayh-Dole patent, but only 18 (2%) had solely Bayh-Dole patents. Of 2832 drugs with patents listed for 1985 to 2023, 142 (5%) had a Bayh-Dole patent, but only 38 (1%) had solely Bayh-Dole patents. Of 1213 drugs with Orange Book patents listed in October 2023, 41 (3%) had a Bayh-Dole patent, but only 14 (1%) had solely Bayh-Dole patents.</p><p><strong>Conclusion and relevance: </strong>This cross-sectional study found that, although Bayh-Dole march-in rights could remove patent barriers to generic entry for a few drugs, their overall effect would be limited.</p>","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":null,"pages":null},"PeriodicalIF":9.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11530938/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142559438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
JAMA Health Forum. 美国医学会杂志健康论坛。
IF 9.5 Q1 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-11-01 DOI: 10.1001/jamahealthforum.2024.0536
{"title":"JAMA Health Forum.","authors":"","doi":"10.1001/jamahealthforum.2024.0536","DOIUrl":"https://doi.org/10.1001/jamahealthforum.2024.0536","url":null,"abstract":"","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":null,"pages":null},"PeriodicalIF":9.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142559435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Errors in Conflict of Interest Disclosures. 利益冲突披露中的错误。
IF 9.5 Q1 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-11-01 DOI: 10.1001/jamahealthforum.2024.4268
{"title":"Errors in Conflict of Interest Disclosures.","authors":"","doi":"10.1001/jamahealthforum.2024.4268","DOIUrl":"10.1001/jamahealthforum.2024.4268","url":null,"abstract":"","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":null,"pages":null},"PeriodicalIF":9.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11530933/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142559434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cannabis Use During Early Pregnancy Following Recreational Cannabis Legalization. 娱乐性大麻合法化后怀孕早期的大麻使用情况。
IF 9.5 Q1 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-11-01 DOI: 10.1001/jamahealthforum.2024.3656
Kelly C Young-Wolff, Natalie E Slama, Lyndsay A Avalos, Alisa A Padon, Lynn D Silver, Sara R Adams, Monique B Does, Deborah Ansley, Carley Castellanos, Cynthia I Campbell, Stacey E Alexeeff
<p><strong>Importance: </strong>It is unknown whether state recreational cannabis legalization (RCL) is related to increased rates of prenatal cannabis use or whether RCL-related changes vary with cannabis screening methods or the local policy environment.</p><p><strong>Objective: </strong>To test whether RCL in California was associated with changes in prenatal cannabis use rates, whether changes were evident in both self-report and urine toxicology testing, and whether rates varied by local policies banning vs allowing adult-use retailers post-RCL.</p><p><strong>Design, setting, and participants: </strong>This population-based time-series study used data from pregnancies in Kaiser Permanente Northern California universally screened for cannabis use during early pregnancy by self-report and toxicology testing from January 1, 2012, to December 31, 2019. Analyses were conducted from September 2022 to August 2024.</p><p><strong>Exposures: </strong>California state RCL passage (November 9, 2016) and implementation of legal sales (January 1, 2018) were examined with a 1-month lag. Local policies allowing vs banning medical retailers pre-RCL and adult-use retailers post-RCL were also examined.</p><p><strong>Main outcomes and measures: </strong>Any prenatal cannabis use was based on screening at entrance to prenatal care (typically at 8-10 weeks' gestation) and defined as (1) a positive urine toxicology test result or self-report, (2) a positive urine toxicology test result, or (3) self-report. Interrupted time series models were fit using Poisson regression, adjusting for age, race and ethnicity, and neighborhood deprivation index.</p><p><strong>Results: </strong>The sample of 300 993 pregnancies (236 327 unique individuals) comprised 25.9% Asian individuals, 6.4% Black individuals, 26.0% Hispanic individuals, 37.7% White individuals, and 4.1% individuals of other, multiple, or unknown race, with a mean (SD) age of 30.3 (5.4) years. Before RCL implementation, rates of prenatal cannabis use rose steadily from 4.5% in January 2012 to 7.1% in January 2018. There was no change in use rates at the time of RCL passage (level change rate ratio [RR], 1.03; 95% CI, 0.96-1.11) and a statistically significant increase in rates in the first month after RCL implementation, increasing to 8.6% in February 2018 (level change RR, 1.10; 95% CI, 1.04-1.16). Results were similar when defining prenatal cannabis use by (1) a toxicology test or (2) self-report. In local policy analyses, the post-RCL implementation increase in use was only found among those in jurisdictions allowing adult-use cannabis retailers (allowed RR, 1.21; 95% CI, 1.10-1.33; banned RR, 1.01; 95% CI, 0.93-1.10).</p><p><strong>Conclusions and relevance: </strong>In this time-series study, RCL implementation in California was associated with an increase in rates of cannabis use during early pregnancy, defined by both self-report and toxicology testing, driven by individuals living in jurisdictions that a
重要性:目前尚不清楚各州娱乐大麻合法化(RCL)是否与产前大麻使用率增加有关,也不清楚与 RCL 有关的变化是否因大麻筛查方法或当地政策环境而异:目的: 检验加利福尼亚州的 RCL 是否与产前大麻使用率的变化有关,自我报告和尿液毒理学检测中的变化是否明显,以及 RCL 后禁止与允许成人使用零售商的地方政策是否会导致产前大麻使用率的变化:这项基于人群的时间序列研究使用了北加州凯泽医疗机构(Kaiser Permanente Northern California)从 2012 年 1 月 1 日至 2019 年 12 月 31 日通过自我报告和毒理学检测对怀孕早期使用大麻的孕妇进行普遍筛查的数据。分析时间为 2022 年 9 月至 2024 年 8 月:加利福尼亚州 RCL 的通过(2016 年 11 月 9 日)和合法销售的实施(2018 年 1 月 1 日)滞后 1 个月进行研究。此外,还对 RCL 之前允许与禁止医疗零售商以及 RCL 之后允许与禁止成人使用零售商的地方政策进行了研究:任何产前大麻使用情况均基于产前护理入门时(通常在妊娠 8-10 周时)的筛查,并定义为(1)尿液毒理学检测结果呈阳性或自我报告,(2)尿液毒理学检测结果呈阳性,或(3)自我报告。采用泊松回归法拟合间断时间序列模型,并对年龄、种族和民族以及邻里贫困指数进行调整:样本中有 300 993 名孕妇(236 327 人),其中亚裔占 25.9%,黑人占 6.4%,西班牙裔占 26.0%,白人占 37.7%,其他、多重或未知种族占 4.1%,平均(标清)年龄为 30.3 (5.4)岁。在实施 RCL 之前,产前大麻使用率从 2012 年 1 月的 4.5% 稳步上升至 2018 年 1 月的 7.1%。在 RCL 通过时,使用率没有变化(水平变化率比 [RR],1.03;95% CI,0.96-1.11),而在 RCL 实施后的第一个月,使用率出现了统计意义上的显著增长,在 2018 年 2 月增至 8.6%(水平变化率比,1.10;95% CI,1.04-1.16)。当通过(1)毒理学测试或(2)自我报告来定义产前大麻使用时,结果相似。在地方政策分析中,只有在允许成人使用大麻零售商的辖区内,才会发现 RCL 实施后使用量的增加(允许 RR,1.21;95% CI,1.10-1.33;禁止 RR,1.01;95% CI,0.93-1.10):在这项时间序列研究中,加利福尼亚州 RCL 的实施与妊娠早期大麻使用率的增加有关,妊娠早期大麻使用率由自我报告和毒理学测试确定,由生活在允许成人使用零售商辖区的个人驱动。
{"title":"Cannabis Use During Early Pregnancy Following Recreational Cannabis Legalization.","authors":"Kelly C Young-Wolff, Natalie E Slama, Lyndsay A Avalos, Alisa A Padon, Lynn D Silver, Sara R Adams, Monique B Does, Deborah Ansley, Carley Castellanos, Cynthia I Campbell, Stacey E Alexeeff","doi":"10.1001/jamahealthforum.2024.3656","DOIUrl":"10.1001/jamahealthforum.2024.3656","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;It is unknown whether state recreational cannabis legalization (RCL) is related to increased rates of prenatal cannabis use or whether RCL-related changes vary with cannabis screening methods or the local policy environment.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To test whether RCL in California was associated with changes in prenatal cannabis use rates, whether changes were evident in both self-report and urine toxicology testing, and whether rates varied by local policies banning vs allowing adult-use retailers post-RCL.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;This population-based time-series study used data from pregnancies in Kaiser Permanente Northern California universally screened for cannabis use during early pregnancy by self-report and toxicology testing from January 1, 2012, to December 31, 2019. Analyses were conducted from September 2022 to August 2024.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Exposures: &lt;/strong&gt;California state RCL passage (November 9, 2016) and implementation of legal sales (January 1, 2018) were examined with a 1-month lag. Local policies allowing vs banning medical retailers pre-RCL and adult-use retailers post-RCL were also examined.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;Any prenatal cannabis use was based on screening at entrance to prenatal care (typically at 8-10 weeks' gestation) and defined as (1) a positive urine toxicology test result or self-report, (2) a positive urine toxicology test result, or (3) self-report. Interrupted time series models were fit using Poisson regression, adjusting for age, race and ethnicity, and neighborhood deprivation index.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The sample of 300 993 pregnancies (236 327 unique individuals) comprised 25.9% Asian individuals, 6.4% Black individuals, 26.0% Hispanic individuals, 37.7% White individuals, and 4.1% individuals of other, multiple, or unknown race, with a mean (SD) age of 30.3 (5.4) years. Before RCL implementation, rates of prenatal cannabis use rose steadily from 4.5% in January 2012 to 7.1% in January 2018. There was no change in use rates at the time of RCL passage (level change rate ratio [RR], 1.03; 95% CI, 0.96-1.11) and a statistically significant increase in rates in the first month after RCL implementation, increasing to 8.6% in February 2018 (level change RR, 1.10; 95% CI, 1.04-1.16). Results were similar when defining prenatal cannabis use by (1) a toxicology test or (2) self-report. In local policy analyses, the post-RCL implementation increase in use was only found among those in jurisdictions allowing adult-use cannabis retailers (allowed RR, 1.21; 95% CI, 1.10-1.33; banned RR, 1.01; 95% CI, 0.93-1.10).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions and relevance: &lt;/strong&gt;In this time-series study, RCL implementation in California was associated with an increase in rates of cannabis use during early pregnancy, defined by both self-report and toxicology testing, driven by individuals living in jurisdictions that a","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":null,"pages":null},"PeriodicalIF":9.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11530934/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142559432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Surgeon Workforce in Underserved Communities. 服务不足社区的外科医生队伍。
IF 9.5 Q1 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-11-01 DOI: 10.1001/jamahealthforum.2024.3531
Crystal D Taylor, Sara L Schaefer, Adrian Diaz, Nicholas Kunnath, John W Scott, Andrew M Ibrahim
{"title":"Surgeon Workforce in Underserved Communities.","authors":"Crystal D Taylor, Sara L Schaefer, Adrian Diaz, Nicholas Kunnath, John W Scott, Andrew M Ibrahim","doi":"10.1001/jamahealthforum.2024.3531","DOIUrl":"https://doi.org/10.1001/jamahealthforum.2024.3531","url":null,"abstract":"","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":null,"pages":null},"PeriodicalIF":9.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142559436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Physician Altruism and Spending, Hospital Admissions, and Emergency Department Visits. 医生利他主义与支出、入院率和急诊就诊率。
IF 9.5 Q1 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-10-04 DOI: 10.1001/jamahealthforum.2024.3383
Lawrence P Casalino, Shachar Kariv, Daniel Markovits, Raymond Fisman, Jing Li

Importance: Altruism-putting the patient first-is a fundamental component of physician professionalism. Evidence is lacking about the relationship between physician altruism, care quality, and spending.

Objective: To determine whether there is a relationship between physician altruism, measures of quality, and spending, hypothesizing that altruistic physicians have better results.

Design, setting, and participants: This cross-sectional study that used a validated economic experiment to measure altruism was carried out between October 2018 and November 2019 using a nationwide sample of US primary care physicians and cardiologists. Altruism data were linked to 2019 Medicare claims and multivariable regressions were used to examine the relationship between altruism and quality and spending measures. Overall, 250 physicians in 43 medical practices that varied in size, location, and ownership, and 7626 Medicare fee-for-service beneficiaries attributed to the physicians were included. The analysis was conducted from April 2022 to August 2024.

Exposure: Physicians completed a widely used modified dictator-game style web-based experiment; based on their responses, they were categorized as more or less altruistic.

Main measures: Potentially preventable hospital admissions, potentially preventable emergency department visits, and Medicare spending.

Results: In all, 1599 beneficiaries (21%) were attributed to the 45 physicians (18%) categorized as altruistic and 6027 patients were attributed to the 205 physicians not categorized as altruistic. Adjusting for patient, physician, and practice characteristics, patients of altruistic physicians had a lower likelihood of any potentially preventable admission (odds ratio [OR], 0.60; 95% CI, 0.38-0.97; P = .03) and any potentially preventable emergency department visit (OR, 0.64; CI, 0.43-0.94; P = .02). Adjusted spending was 9.26% lower (95% CI, -16.24% to -2.27%; P = .01).

Conclusions and relevance: This cross-sectional study found that Medicare patients treated by altruistic physicians had fewer potentially preventable hospitalizations and emergency department visits and lower spending. Policymakers and leaders of hospitals, medical practices, and medical schools may want to consider creating incentives, organizational structures, and cultures that may increase, or at least do not decrease, physician altruism. Further research should seek to identify these and other modifiable factors, such as physician selection and training, that may shape physician altruism. Research could also analyze the relationship between altruism and quality and spending in additional medical practices, specialties, and countries, and use additional measures of quality and of patient experience.

重要性:利他主义--把病人放在第一位--是医生职业精神的基本组成部分。有关医生利他主义、医疗质量和支出之间关系的证据尚缺:目的:确定医生利他主义、医疗质量和支出之间是否存在关系,假设利他主义医生的医疗效果更好:这项横断面研究使用一个经过验证的经济实验来衡量利他主义,研究于 2018 年 10 月至 2019 年 11 月期间进行,使用的是美国全国范围内的初级保健医生和心脏病专家样本。利他主义数据与 2019 年医疗保险理赔相关联,并使用多变量回归来检验利他主义与质量和支出指标之间的关系。研究共纳入了 43 家医疗机构的 250 名医生(这些医疗机构的规模、地点和所有权各不相同)和 7626 名医疗保险付费服务受益人。分析时间为 2022 年 4 月至 2024 年 8 月:医生们完成了一项广泛使用的改良独裁者游戏式网络实验;根据他们的回答,他们被分为利他主义较强或较弱的类型:主要衡量指标:潜在可预防的入院率、潜在可预防的急诊就诊率和医疗保险支出:共有 1599 名受益人(21%)归属于 45 名被归类为利他主义的医生(18%),6027 名患者归属于 205 名未被归类为利他主义的医生。在对患者、医生和诊所特征进行调整后,利他主义医生的患者接受任何潜在可预防入院治疗(几率比 [OR],0.60;95% CI,0.38-0.97;P = .03)和任何潜在可预防急诊就诊(OR,0.64;CI,0.43-0.94;P = .02)的可能性较低。调整后的支出降低了 9.26% (95% CI, -16.24% to -2.27%; P = .01):这项横断面研究发现,接受利他主义医生治疗的医疗保险患者的潜在可预防住院和急诊就诊次数较少,花费也较低。医院、医疗机构和医学院校的决策者和领导者可能需要考虑建立激励机制、组织结构和文化,以提高或至少不降低医生的利他主义。进一步的研究应设法确定这些因素和其他可改变的因素,如医生的选择和培训,这些因素可能会影响医生的利他主义。研究还可以分析利他主义与其他医疗实践、专科和国家的质量和支出之间的关系,并使用更多的质量和患者体验衡量标准。
{"title":"Physician Altruism and Spending, Hospital Admissions, and Emergency Department Visits.","authors":"Lawrence P Casalino, Shachar Kariv, Daniel Markovits, Raymond Fisman, Jing Li","doi":"10.1001/jamahealthforum.2024.3383","DOIUrl":"https://doi.org/10.1001/jamahealthforum.2024.3383","url":null,"abstract":"<p><strong>Importance: </strong>Altruism-putting the patient first-is a fundamental component of physician professionalism. Evidence is lacking about the relationship between physician altruism, care quality, and spending.</p><p><strong>Objective: </strong>To determine whether there is a relationship between physician altruism, measures of quality, and spending, hypothesizing that altruistic physicians have better results.</p><p><strong>Design, setting, and participants: </strong>This cross-sectional study that used a validated economic experiment to measure altruism was carried out between October 2018 and November 2019 using a nationwide sample of US primary care physicians and cardiologists. Altruism data were linked to 2019 Medicare claims and multivariable regressions were used to examine the relationship between altruism and quality and spending measures. Overall, 250 physicians in 43 medical practices that varied in size, location, and ownership, and 7626 Medicare fee-for-service beneficiaries attributed to the physicians were included. The analysis was conducted from April 2022 to August 2024.</p><p><strong>Exposure: </strong>Physicians completed a widely used modified dictator-game style web-based experiment; based on their responses, they were categorized as more or less altruistic.</p><p><strong>Main measures: </strong>Potentially preventable hospital admissions, potentially preventable emergency department visits, and Medicare spending.</p><p><strong>Results: </strong>In all, 1599 beneficiaries (21%) were attributed to the 45 physicians (18%) categorized as altruistic and 6027 patients were attributed to the 205 physicians not categorized as altruistic. Adjusting for patient, physician, and practice characteristics, patients of altruistic physicians had a lower likelihood of any potentially preventable admission (odds ratio [OR], 0.60; 95% CI, 0.38-0.97; P = .03) and any potentially preventable emergency department visit (OR, 0.64; CI, 0.43-0.94; P = .02). Adjusted spending was 9.26% lower (95% CI, -16.24% to -2.27%; P = .01).</p><p><strong>Conclusions and relevance: </strong>This cross-sectional study found that Medicare patients treated by altruistic physicians had fewer potentially preventable hospitalizations and emergency department visits and lower spending. Policymakers and leaders of hospitals, medical practices, and medical schools may want to consider creating incentives, organizational structures, and cultures that may increase, or at least do not decrease, physician altruism. Further research should seek to identify these and other modifiable factors, such as physician selection and training, that may shape physician altruism. Research could also analyze the relationship between altruism and quality and spending in additional medical practices, specialties, and countries, and use additional measures of quality and of patient experience.</p>","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":null,"pages":null},"PeriodicalIF":9.5,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142401936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
JAMA Health Forum. 美国医学会杂志健康论坛。
IF 9.5 Q1 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-10-04 DOI: 10.1001/jamahealthforum.2024.0535
{"title":"JAMA Health Forum.","authors":"","doi":"10.1001/jamahealthforum.2024.0535","DOIUrl":"10.1001/jamahealthforum.2024.0535","url":null,"abstract":"","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":null,"pages":null},"PeriodicalIF":9.5,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142373564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unwinding Medicaid Eligibility: Lessons for Health Policy. 取消医疗补助资格:对医疗政策的启示。
IF 9.5 Q1 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-10-04 DOI: 10.1001/jamahealthforum.2024.4487
Michelle Bedoya, Joshua M Sharfstein
{"title":"Unwinding Medicaid Eligibility: Lessons for Health Policy.","authors":"Michelle Bedoya, Joshua M Sharfstein","doi":"10.1001/jamahealthforum.2024.4487","DOIUrl":"https://doi.org/10.1001/jamahealthforum.2024.4487","url":null,"abstract":"","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":null,"pages":null},"PeriodicalIF":9.5,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142512792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
JAMA Health Forum
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1